| 000 | 01245 a2200265 4500 | ||
|---|---|---|---|
| 001 | 1040281427 | ||
| 005 | 20250328151426.0 | ||
| 008 | 250324042024xx eng | ||
| 020 |
_a9781040281420 _qEA |
||
| 037 |
_bTaylor & Francis _cGBP 115.00 _fBB |
||
| 040 | _a01 | ||
| 041 | _aeng | ||
| 072 | 7 |
_aMJCL _2thema |
|
| 072 | 7 |
_aMJCL _2bic |
|
| 072 | 7 |
_aMED045000 _2bisac |
|
| 072 | 7 |
_aMED000000 _2bisac |
|
| 072 | 7 |
_aMED062000 _2bisac |
|
| 072 | 7 |
_a616.994061 _2bisac |
|
| 100 | 1 | _aMario A. Dicato | |
| 245 | 1 | 0 | _aMedical Management of Cancer-treatment Induced Emesis |
| 250 | _a1 | ||
| 260 |
_bCRC Press _c20241101 |
||
| 300 | _a248 p | ||
| 520 | _bNausea and vomiting are two of the most common side-effects of anti-cancer treatment, and the discovery and clinical application of 5-hydroxytryptamine3 receptor antagonists has transformed the management of these side effects, resulting in a much improved quality of life for cancer patients. This text presents a detailed overview of the management of cancer-treatment induced emesis in a number of different treatment settings, and focuses on the mechanisms and use of 5-HT3 receptor antagonists. Contributions are also included from the points of view of the nurse and the patient. | ||
| 999 |
_c8527 _d8527 |
||